Duopharma sees satisfactory results this year


The pharmaceutical company said it had encountered a myriad of challenges in 2023.

PETALING JAYA: Duopharma Biotech Bhd aims to deliver a satisfactory performance in 2024, underpinned by the positive advancements and anticipated growth in the economy and industry.

In a filing with Bursa Malaysia, the pharmaceutical company said it had encountered a myriad of challenges in 2023, which exerted pressure on its manufacturing margins, thus influencing the group’s overall profitability in 2023.

Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Outsourcing no more the in-thing
An oil price to pay for conflict
Sights too high on highways?
Win some, lose some
Strong wind in its sails
AEON Bank goes live with Zakat feature on digital banking app
The real costs of cheap homes
Balance urban renewal with responsibility
The RM1.2 trillion shadow
Celebrate the festive season with greater rewards from Maybank

Others Also Read